This recent capital raise will allow us to continue the clinical development of our lead product candidate, AC220, which is currently in a Phase 2 pivotal trial in Acute Myeloid Leukemia. This financing also provides for the continued development of our other two clinical assets, AC430 and AC480, both of which are in Phase 1 trials.

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

11080 Roselle St.
San Diego, CA 92121
USA

Phone

(858) 334-2100

Website

www.ambitbio.com

Email Address

[email protected]

Overview

Ambit Biosciences is a biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer.

Profile

Social Media

Ambit Biosciences Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Michael Martino

Chief Financial Officer

Alan Fuhrman

Chief Medical Officer

Athena Countouriotis

Browse more venture capital transactions:

Prev: 6/10/2011: Agile Energy venture capital transaction
Next: 6/10/2011: Intarcia Therapeutics venture capital transaction

Share this article

About Our VC Transactions Data

Our team works diligently to document all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary